Navigation Links
Okyanos Center for Regenerative Medicine Announces New Treatment Option for Patients with Diffuse Scleroderma Based on STAR Trial Protocol

Okyanos Center for Regenerative Medicine today announced that Okyanos is now offering a new and advanced protocol for diffuse scleroderma based on the well-established protocol implemented in the STAR clinical trial.

Earlier this year Cytori Therapeutics, Inc., reported the findings of the STAR trial which used adipose derived regenerative cells (ADRCs) to treat scleroderma affecting the hands and fingers. Using 19 leading medical centers in the United States, the double-blind, randomized, placebo-controlled trial enrolled and evaluated 88 participants, 51 of whom had diffuse scleroderma, a more severe form of the disease. At the end of the study, those patients treated for diffuse cutaneous scleroderma showed significant improvements in hand function and functional disability scores, 48 weeks after treatment.

Okyanos’ new treatment protocol brings hope to the more than 50,000 Americans suffering on a daily basis with diffuse scleroderma, the most severe type of this autoimmune disease. This protocol, which is currently not being offered in the United States, is an important therapeutic option for the skin manifestations of this type of systemic scleroderma and is now being offered at the Okyanos Center for Regenerative Medicine in Freeport, Grand Bahama.

“Through the delivery of regenerative therapies, our mission at Okyanos is to restore and extend healthy living,” said Vincent Burton, MBBS, FRCA and President at Okyanos. “We are offering this advanced protocol as an opportunity for symptomatic relief for patients with skin manifestations of diffuse scleroderma, as well as to allow treating physicians to consider an additional option to help their patients feel better.”

“ADRCs are an active stem cell population. The evidence of clinical benefit in the STAR trial parallels the effects we see in patients with multiple chronic conditions who we treat with ADRCs,” said Dr. Marc Penn, MD, PhD, FACC and Director of Research & Development at Okyanos. “Our new protocol for diffuse cutaneous scleroderma is another significant example in Okyanos’ commitment to expanding our offering of evidence-based regenerative medicine treatments.”

As an autoimmune disease, scleroderma damages connective tissue and can be difficult to diagnose. One of the most serious classifications of scleroderma is systemic scleroderma where the “sclerosis” or hardening of the tissue often occurs in the internal systems of the body, involving the skin in addition to various internal organs such as the lungs, kidneys, heart and gastrointestinal organs. The two categories of systemic scleroderma are limited and diffuse with the latter being more severe.

At the end of the study, those patients enrolled in the STAR trial with diffuse scleroderma showed improvements in the Cochin Hand Function Score and the Health Assessment Questionnaire-Disability Index (HAQ-DI), a measure of functional disability and an important secondary endpoint, which met or exceeded the published criteria for minimally important clinical differences in these measures (6.5 points for Cochin1, 0.22 points for HAQ-DI2).

The protocol used by Okyanos involves patients undergoing fat harvest through small volume liposuction under anesthesia. This lipoaspirate is then processed to produce ADRCs for same-day subcutaneous administration into all fingers of both hands. In addition the patient will receive an intravenous infusion of ADRCs. The safety profile for ADRCs is well-established in regenerative medicine with no toxicity in thousands of patient data sets. All patients treated at Okyanos who consent, including those treated for diffuse scleroderma, are followed post-treatment and efficacy data is obtained by a third-party contract research organization.

To learn more about adult stem cell treatment for diffuse scleroderma at Okyanos, please visit

Combining state-of-the art technologies delivered in the first cell therapy center of excellence in the world, Okyanos is a leading adult stem cell therapy provider. Okyanos Center for Regenerative Medicine helps people living with chronic, degenerative diseases return to a more normal life through a treatment approach using a patient’s own fat-derived stem cells. Based in Freeport, Grand Bahama, Okyanos is fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to US surgical center standards. The literary name Okyanos, the Greek god of the river Okeanos, symbolizes restoration of blood flow. Learn more at

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related medicine news :

1. Robert Russell Named Director of Physician Engagement at Okyanos Center for Regenerative Medicine
2. Okyanos Cell Therapy’s Dr. Eric Duckers Joins Prestigious Regenera Global Conference Program
3. Okyanos Cell Therapy Partners with Regenera Global as Platinum Sponsor for Upcoming Conference
4. Okyanos Celebrates 1-Year Anniversary Milestones
5. Dr. Jeffrey Hartog Joins Okyanos Medical Team as Cell Therapy Surgeon
6. Saving Lives: Okyanos Cell Therapy Hits Milestone with Over 100 Patients Treated
7. Okyanos Cell Therapy Welcomes Community in First Open House
8. Okyanos Study Finds Orthopedic Patients Plagued with Pain
9. Okyanos Cell Therapy: From Burnout to Fearless
10. Okyanos Stem Cell Therapy Launches Orthopedic Lifestyle Survey
11. Okyanos Treats First Patients with Cell Therapy
Post Your Comments:
(Date:7/9/2019)... (PRWEB) , ... July 10, 2019 , ... ... to the role of Client Services Manager and will lead the growing team ... new role at First Healthcare Compliance and look forward to further developing new ...
(Date:7/9/2019)... ... 09, 2019 , ... Human cytomegalovirus (HCMV) may not be a household name ... Veterinary Medicine at UMD, half of the population walking around campus is likely to ... of your life and can flare up whenever your immune system is severely compromised, ...
(Date:7/9/2019)... ... July 09, 2019 , ... A2LA is pleased to announce the accreditation ... oils, and solids. GEL Laboratories is based in Charleston, South Carolina, and is the ... first laboratory in the field of environmental testing to expand their scope to include ...
(Date:7/9/2019)... ... July 09, 2019 , ... Anxiety help can often feel out of reach ... A new online therapy platform called Emote seeks to change this for ... through their mobile device, tablet or computer to highly qualified licensed therapists online. Easily ...
(Date:7/9/2019)... ... 09, 2019 , ... Advanced Intelligent Systems (AIS) , ... shortage problems in agriculture, will demonstrate their flagship autonomous custom robot, called ... North America’s leading trade show for the horticulture industry. , “We are ...
Breaking Medicine News(10 mins):
(Date:7/10/2019)... ... July 10, 2019 , ... is the first website aimed ... months, does CBD actually work? It seems like depending on what you read, CBD ... instead aims to get testimonials of real CBD users, who are attempting to ease ...
(Date:7/10/2019)... ... 2019 , ... Successful actor and philanthropist, Laurence Fishburne, is ... of healthcare and how these costs affect American consumers. , The episode addresses ... painful decisions families face between paying for essential health services they require and ...
(Date:7/9/2019)... ... 10, 2019 , ... Women’s Excellence’s goal is treating the ... in-depth interpretation of symptoms, evaluate a women’s lifestyle, and conduct physical examination and ... wants and needs for your menopausal management. Our team specializes in bioidentical ...
Breaking Medicine Technology: